Assignee
DYNE THERAPEUTICS INC
US·54 granted patents·52 pending applications·1,245 citations·filing 2019–2025
Top patents by PatentIndex Score
106 records- 0199US12370264B1Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subjectDYNE THERAPEUTICS INC·Filed 2025·Granted Jul 29, 2025·2 cites·30 claims
- 0299US12357703B2Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skippingDYNE THERAPEUTICS INC·Filed 2025·Granted Jul 15, 2025·2 cites·30 claims
- 0399US12329824B1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2025·Granted Jun 17, 2025·4 cites·30 claims
- 0499US12329825B1Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subjectDYNE THERAPEUTICS INC·Filed 2025·Granted Jun 17, 2025·4 cites·30 claims
- 0599US12325753B2Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Jun 10, 2025·5 cites·30 claims
- 0699US12319743B2Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subjectDYNE THERAPEUTICS INC·Filed 2024·Granted Jun 3, 2025·5 cites·30 claims
- 0799US12263225B2Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Apr 1, 2025·11 cites·30 claims
- 0899US12239717B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Mar 4, 2025·13 cites·30 claims
- 0999US12239716B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Mar 4, 2025·13 cites·30 claims
- 1099US12173079B2Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotideDYNE THERAPEUTICS INC·Filed 2024·Granted Dec 24, 2024·14 cites·30 claims
- 1199US12173078B2Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotideDYNE THERAPEUTICS INC·Filed 2024·Granted Dec 24, 2024·14 cites·30 claims
- 1299US12144867B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Nov 19, 2024·14 cites·19 claims
- 1399US12144868B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Nov 19, 2024·14 cites·19 claims
- 1499US12102687B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Oct 1, 2024·17 cites·30 claims
- 1599US12097263B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Sep 24, 2024·18 cites·21 claims
- 1699US12018087B2Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subjectDYNE THERAPEUTICS INC·Filed 2023·Granted Jun 25, 2024·23 cites·27 claims
- 1799US12012460B2Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotideDYNE THERAPEUTICS INC·Filed 2023·Granted Jun 18, 2024·22 cites·28 claims
- 1899US12005124B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2023·Granted Jun 11, 2024·23 cites·30 claims
- 1999US11986537B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2023·Granted May 21, 2024·24 cites·19 claims
- 2099US11969475B2Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2023·Granted Apr 30, 2024·25 cites·30 claims
- 2199US11911484B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2021·Granted Feb 27, 2024·28 cites·22 claims
- 2299US11844843B2Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2023·Granted Dec 19, 2023·30 cites·30 claims
- 2399US11839660B2Anti-transferrin receptor antibody and uses thereofDYNE THERAPEUTICS INC·Filed 2023·Granted Dec 12, 2023·30 cites·16 claims
- 2499US11833217B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2023·Granted Dec 5, 2023·30 cites·20 claims
- 2599US11795233B2Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotideDYNE THERAPEUTICS INC·Filed 2023·Granted Oct 24, 2023·32 cites·30 claims
- 2699US11795234B2Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotideDYNE THERAPEUTICS INC·Filed 2023·Granted Oct 24, 2023·32 cites·30 claims
- 2799US11787869B2Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weaknessDYNE THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·32 cites·30 claims
- 2899US11771776B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Granted Oct 3, 2023·32 cites·19 claims
- 2999US11759525B1Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Sep 19, 2023·32 cites·22 claims
- 3099US11679161B2Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Jun 20, 2023·38 cites·25 claims
- 3199US11672872B2Anti-transferrin receptor antibody and uses thereofDYNE THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·37 cites·21 claims
- 3299US11648318B2Anti-transferrin receptor (TFR) antibody and uses thereofDYNE THERAPEUTICS INC·Filed 2022·Granted May 16, 2023·37 cites·9 claims
- 3399US11638761B2Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted May 2, 2023·47 cites·24 claims
- 3499US11633498B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Apr 25, 2023·37 cites·30 claims
- 3599US11633496B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Granted Apr 25, 2023·36 cites·20 claims
- 3699US11518816B2Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Dec 6, 2022·46 cites·23 claims
- 3799US11497815B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Granted Nov 15, 2022·46 cites·20 claims
- 3899US11390682B2Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Jul 19, 2022·48 cites·23 claims
- 3999US11369689B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Granted Jun 28, 2022·48 cites·20 claims
- 4099US11286305B2Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNADYNE THERAPEUTICS INC·Filed 2021·Granted Mar 29, 2022·64 cites·18 claims
- 4199US11248056B1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2021·Granted Feb 15, 2022·50 cites·12 claims
- 4299US11168141B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2021·Granted Nov 9, 2021·53 cites·12 claims
- 4399US11111309B2Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting DUX4DYNE THERAPEUTICS INC·Filed 2021·Granted Sep 7, 2021·65 cites·21 claims
- 4498US12280122B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Apr 22, 2025·5 cites·24 claims
- 4597US11931421B2Muscle targeting complexes and formulations for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2023·Granted Mar 19, 2024·26 cites·7 claims
- 4695US12128109B2Muscle targeting complexes and formulations for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·17 cites·28 claims
- 4792US2025360223A1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4892US2025382375A1Muscle-targeting complexes and uses thereofDYNE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4990US12440574B2Muscle targeting complexes and formulations for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Oct 14, 2025·0 cites·22 claims
- 5090US12403203B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Sep 2, 2025·0 cites·19 claims
Showing the top 50 of 106 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when DYNE THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →